Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001437749-24-035866
Filing Date
2024-11-20
Accepted
2024-11-20 16:33:12
Documents
2
Period of Report
2024-11-18

Document Format Files

Seq Description Document Type Size
1 FORM 3 rdgdoc.html 3  
1 FORM 3 rdgdoc.xml 3 1513
2 nassifpoa.htm EX-24 10948
  Complete submission text file 0001437749-24-035866.txt   14062
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Issuer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1, SUITE 300 AUSTIN TX 78731
Business Address
Nassif Freda (Reporting) CIK: 0002045036 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-41905 | Film No.: 241480852